Your browser doesn't support javascript.
loading
The prognostic value of the post-treatment serum CA 125 level in patients with advanced endometrial cancer.
Muzykiewicz, Konrad P; Iwanska, Ewa; Pniewska, Karolina W; Janeczek, Maja; Nowak-Jastrzab, Malgorzata; Kalamacki, Andrzej; Karolewski, Kazimierz; Blecharz, Pawel.
Afiliación
  • Muzykiewicz KP; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland. konrad.muzykiewicz@gmail.com.
  • Iwanska E; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Pniewska KW; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Janeczek M; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Nowak-Jastrzab M; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Kalamacki A; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Karolewski K; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
  • Blecharz P; Department of Gynecologic Oncology, Maria Sklodowska-Curie National Research Institute of Oncology, Branch in Cracow, Poland, Poland.
Ginekol Pol ; 2023 Dec 21.
Article en En | MEDLINE | ID: mdl-38126890
ABSTRACT

OBJECTIVES:

The goal of this analysis was to assess the prognostic value of the post-treatment serum CA 125 level in each member of a group of advanced endometrial cancer (aEC) patients in comparison to other clinical and pathological parameters. MATERIAL AND

METHODS:

Records of 266 patients treated at the Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Cracow Branch between the years 2006 and 2018 were included in the study. Follow-up ranged from 1 to 138 months. Progression free survival (PFS) and overall survival (OS) were set as the endpoints. The tests chi-squared, Fisher, log-rank, Mann-Whitney, Kruskal-Wallis and Cox proportional hazard ratio were used for statistical analyses.

RESULTS:

In the analysed group, there was a significant association between an elevated serum CA 125 level following adjuvant treatment and shorter PFS and OS. After setting a cut-off value for CA 125 there was a statistically significant correlation between the marker and PFS and OS. Multivariate analysis indicated that the post-treatment serum CA 125 level is an independent prognostic factor of the course of aEC.

CONCLUSIONS:

The post-treatment serum CA 125 level correlates significantly with both PFS and OS in each patient with aEC. The marker is an independent prognostic factor in this group. A low post-treatment level of the marker is a strong indicator of good 5-year survival, with 82% of patients reaching 5-year OS.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ginekol Pol Año: 2023 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Ginekol Pol Año: 2023 Tipo del documento: Article País de afiliación: Polonia Pais de publicación: Polonia